

ERRATUM

ERRATUM: Better growth outcomes in GH-deficient children treated younger than 2 years of age

Tilman Robert Rohrer¹, Primož Kotnik^{2,3}, Bradley S Miller⁴, Nicky Kelepouris⁵, Anne Helene Olsen⁶, Alberto Pietropoli⁷, Michel Polak^{8,9} and Jo Blair¹⁰

¹Division of Pediatric Endocrinology, Department of Pediatrics and Neonatology, University Children's Hospital, Saarland University Medical Center, Homburg, Germany

²Department of Pediatrics, Faculty of Medicine, University Medical Center Ljubljana, Ljubljana, Slovenia

³Department of Pediatric Endocrinology, Diabetes and Metabolism, University Children's Hospital Ljubljana, University Medical Center, Ljubljana, Slovenia

⁴Pediatric Endocrinology, University of Minnesota Medical School, MHealth Fairview Masonic Children's Hospital, Minneapolis, Minnesota, USA

⁵Rare Endocrine Disorders, Novo Nordisk Inc, Plainsboro, New Jersey, USA

⁶Epidemiology, Novo Nordisk A/S, Søborg, Denmark

⁷Global Medical Affairs, Novo Nordisk Health Care AG, Zurich, Switzerland

⁸Hôpital Universitaire Necker Enfants Malades, Assistance Publique-Hôpitaux de Paris, Paris, France

⁹Institut IMAGINE, Centre de Référence des Maladies Endocriniennes Rares de la Croissance et du Développement, Paris, France

¹⁰Department of Paediatric Endocrinology, Alder Hey Children's NHS Foundation Trust, Liverpool, UK

Correspondence should be addressed to T R Rohrer: Tilman.Rohrer@uniklinikum-saarland.de

The authors and journal apologise for an error in the above paper, which appeared in volume 14, part 9, article ID [e250493](https://doi.org/10.1530/EC-25-0493e). The error relates to Table 4, given on pages 9 and 10, in which the *n* value of the 'Age ≥ 2 years' group was given as *n* = 22,976, when this should have been *n* = 21,976. The Table 4 associated with the version of record has been corrected.

The corrected Table 4 is given in full below:

Table 4 Summary of AEs (NSARs, SARs, and SAEs) by system organ class in children included in the NordiNet[®] IOS and ANSWER program studies, according to the age at growth hormone treatment initiation.

System organ class	Total events, n	Age <2 years				Age ≥2 years	
		n = 882*					
		IGHD (n = 592)		MPHD (n = 290)		n = 21,976*	
		Events, n	Patients, n (%)	Events, n	Patients, n (%)	Events, n	Patients, n (%)
Nervous system disorders	208	2	2 (0.34)	7	5 (1.72) [†]	199	163 (0.74)
Seizure	31	2	2 (0.34)	3	3 (1.03)	26	14 (0.06)
Febrile convulsion	2	-	-	1	1 (0.34)	1	1 (<0.01)
Generalised tonic-clonic seizure	4	-	-	1	1 (0.34)	3	2 (<0.01)
Hypoglycaemic seizure	2	-	-	2	2 (0.69)	-	-
Musculoskeletal and connective tissue disorders	155	2	2 (0.34)	3	3 (1.03)	150	126 (0.57)
Epiphysiolysis	9	-	-	2	2 (0.69)	7	7 (0.03)
Myalgia	16	-	-	1	1 (0.34)	15	15 (0.06)
General disorders and administration-site conditions	98	3	3 (0.51)	8	6 (2.07)	87	79 (0.36)
Hyperthermia	3	-	-	3	2 (0.69)	-	-
Hypothermia	1	-	-	1	1 (0.34)	-	-
Pyrexia	3	1	1 (0.17)	1	1 (0.34)	2	2 (<0.01)
Injection site atrophy	4	-	-	1	1 (0.34)	3	3 (0.01)
Oedema	8	-	-	1	1 (0.34)	7	6 (0.03)
Infections and infestations	55	3	3 (0.51)	16	12 (4.14)	36	28 (0.13)
Gastroenteritis	7	1	1 (0.17)	4	4 (1.38)	2	2 (<0.01)
Gastroenteritis norovirus	1	-	-	1	1 (0.34)	-	-
Gastroenteritis rotavirus	1	-	-	1	1 (0.34)	-	-
Gastroenteritis viral	2	-	-	1	1 (0.34)	1	1 (<0.01)
Cellulitis orbital	1	-	-	1	1 (0.34)	-	-
Infection	2	-	-	1	1 (0.34)	1	1 (<0.01)
Influenza	1	-	-	1	1 (0.34)	-	-
Meningitis pneumococcal	1	-	-	1	1 (0.34)	-	-
Otitis media	2	-	-	1	1 (0.34)	1	1 (<0.01)
Pneumonia	9	-	-	1	1 (0.34)	8	7 (0.03)
Pyelonephritis	1	-	-	1	1 (0.34)	-	-
Respiratory syncytial virus bronchitis	1	-	-	1	1 (0.34)	-	-
Viral upper respiratory tract infection	2	-	-	1	1 (0.34)	1	1 (<0.01)
Neoplasms benign, malignant, and unspecified (incl. cysts and polyps)	50	1	1 (0.17)	0	0	49	43 (0.20)
Gastrointestinal disorders	32	2	1 (0.17)	5	5 (1.72)	25	20 (0.09)
Abdominal pain	2	-	-	1	1 (0.34)	1	1 (<0.01)
Inguinal hernia	2	-	-	1	1 (0.34)	1	1 (<0.01)
Stomatitis	1	-	-	1	1 (0.34)	-	-
Vomiting	10	1	1 (0.17)	2	2 (0.69)	7	7 (0.03)
Metabolism and nutrition disorders	32	0	0	4	4 (1.38)	28	25 (0.11)
Hypoglycaemia	3	-	-	3	3 (1.03)	-	-
Lack of satiety	1	-	-	1	1 (0.34)	-	-
Injury, poisoning, and procedural complications	27	1	1 (0.17)	1	1 (0.34)	25	20 (0.09)
Skin and subcutaneous tissue disorders	23	0	0	2	2 (0.69)	21	20 (0.09)
Psychiatric disorders	19	6	1 (0.17)	0	0	13	11 (0.05)
Investigations	17	1	1 (0.17)	3	3 (1.03)	13	11 (0.05)
Respiratory, thoracic, and mediastinal disorders	13	1	1 (0.17)	1	1 (0.34)	11	9 (0.04)
Endocrine disorders	11	1	1 (0.17)	0	0	10	9 (0.04)
Surgical and medical procedures	11	1	1 (0.17)	2	1 (0.34)	8	8 (0.04)
Congenital, familial, and genetic disorders	9	0	0	1	1 (0.34)	8	7 (0.03)
Eye disorders	8	0	0 (0)	0	0 (0)	8	8 (0.04)
Renal and urinary disorders	8	0	0 (0)	1	1 (0.34)	7	7 (0.03)
Cardiac disorders	5	0	0 (0)	1	1 (0.34)	4	4 (0.02)
Hepatobiliary disorders	4	1	1 (0.17)	0	0	3	3 (0.01)
Reproductive system and breast disorders	4	0	0 (0)	0	0 (0)	4	4 (0.02)
Immune system disorders	3	0	0 (0)	0	0 (0)	3	3 (0.01)

(Continued)

Table 4 Continued.

System organ class	Age <2 years					Age ≥2 years	
	<i>n</i> = 882*						
	Total events, <i>n</i>	IGHD (<i>n</i> = 592)		MPHD (<i>n</i> = 290)		<i>n</i> = 21,976*	
		Events, <i>n</i>	Patients, <i>n</i> (%)	Events, <i>n</i>	Patients, <i>n</i> (%)	Events, <i>n</i>	Patients, <i>n</i> (%)
Vascular disorders	3	0	0 (0)	0	0 (0)	3	3 (0.01)
Blood and lymphatic system disorders	2	0	0 (0)	0	0 (0)	2	2 (0.01)
Ear and labyrinth disorders	2	0	0 (0)	0	0 (0)	2	2 (0.01)
Social circumstances	1	0	0 (0)	0	0 (0)	1	1 (0.01)

IGHD, isolated growth hormone deficiency; IOS, International Outcome Study; MPHD, multiple pituitary hormone deficiency; NSARs, non-serious adverse reactions; SAEs, serious adverse events; SARs, serious adverse reactions; SAS, safety analysis set.

The breakdown of specific NSARs, SAEs, and SARs occurring in >1.0% of participants is presented.

*Patients in each group for the SAS. †Bold values highlight findings for main system organ classes with listed subcategories for children with MPHD.